Posted on 29/03/202108/07/2024The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy
Posted on 26/03/202108/07/2024ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
Posted on 23/03/202108/07/2024Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy
Posted on 23/03/202108/07/2024Genentech Provides Update on Tominersen Program in Manifest Huntington’s Disease: Dosing to stop in Phase III clinical study of tominersen
Posted on 19/03/202108/07/2024Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
